<!DOCTYPE html>
<html lang="en"><head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge"><!-- Begin Jekyll SEO tag v2.8.0 -->
<title>Bladder Malignancies | Pediatric Urology Book</title>
<meta name="generator" content="Jekyll v4.2.2" />
<meta property="og:title" content="Bladder Malignancies" />
<meta name="author" content="Arlen AM, Gundeti MS, López P-J, Rove KO" />
<meta property="og:locale" content="en" />
<meta name="description" content="By Jacqueline Morin, MD &amp; Amanda F. Saltzman, MD Department of Urology, University of Kentucky, Lexington, KY" />
<meta property="og:description" content="By Jacqueline Morin, MD &amp; Amanda F. Saltzman, MD Department of Urology, University of Kentucky, Lexington, KY" />
<link rel="canonical" href="https://beta.pediatricurologybook.com/es/book/chapters/08-43_bladder-malignancies/" />
<meta property="og:url" content="https://beta.pediatricurologybook.com/book/chapters/08-43_bladder-malignancies/" />
<meta property="og:site_name" content="Pediatric Urology Book" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2023-01-29T16:01:05-07:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Bladder Malignancies" />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","author":{"@type":"Person","name":"Arlen AM, Gundeti MS, López P-J, Rove KO"},"dateModified":"2022-08-16T15:46:19-06:00","datePublished":"2023-01-29T16:01:05-07:00","description":"By Jacqueline Morin, MD &amp; Amanda F. Saltzman, MD Department of Urology, University of Kentucky, Lexington, KY","headline":"Bladder Malignancies","mainEntityOfPage":{"@type":"WebPage","@id":"https://beta.pediatricurologybook.com/book/chapters/08-43_bladder-malignancies/"},"url":"https://beta.pediatricurologybook.com/book/chapters/08-43_bladder-malignancies/"}</script>
<!-- End Jekyll SEO tag -->
<meta http-equiv="Content-Language" content="es">
<link rel="alternate" hreflang="en" href="https://beta.pediatricurologybook.com/book/chapters/08-43_bladder-malignancies/"/>
<link rel="alternate" hreflang="es" href="https://beta.pediatricurologybook.com/es/book/chapters/08-43_bladder-malignancies/"/>
<link rel="alternate" hreflang="zh" href="https://beta.pediatricurologybook.com/zh/book/chapters/08-43_bladder-malignancies/"/>
<link rel="alternate" hreflang="pt" href="https://beta.pediatricurologybook.com/pt/book/chapters/08-43_bladder-malignancies/"/>

  <!-- Favicon -->
  <link rel="icon" href="https://beta.pediatricurologybook.com/es/favicon.ico" type="image/x-icon" > <!-- 32×32 -->
  <link rel="icon" href="https://beta.pediatricurologybook.com/assets/site-img/favicons/icon.svg" type="image/svg+xml">    <!-- res independent -->
  <link rel="apple-touch-icon" href="https://beta.pediatricurologybook.com/assets/site-img/favicons/apple-touch-icon.png"> <!-- 180×180 -->
  <link rel="manifest" href="/es/manifest.webmanifest">
  
  <!-- Mobile Metas -->
  <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1.0, shrink-to-fit=no">

  <!-- Analytics --><!-- Vendor CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/fontawesome-free/css/all.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/animate/animate.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/rs-plugin/css/navigation.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/owl.carousel/assets/owl.carousel.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/owl.carousel/assets/owl.theme.default.min.css">
  
  <!-- Theme CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/theme.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/theme-elements.css">

  <!-- Skin CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/skins/skin-pub.css"> 
  
  <!-- Theme Custom CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/custom.css">
  
  <!-- JS Libraries -->
  <script src="https://beta.pediatricurologybook.com/assets/vendor/modernizr/modernizr.min.js"></script>
</head>
<body data-plugin-page-transition>

    <div class="body" aria-label="Content">    
    
    <header id="header" data-plugin-options="{'stickyEnabled': true, 'stickyEnableOnBoxed': true, 'stickyEnableOnMobile': true, 'stickyStartAt': 108, 'stickySetTop': '-109px', 'stickyChangeLogo': true}">
      <div class="header-body">
        <div class="header-container container">
          <div class="header-row">
            <div class="header-column">
              <div class="header-row">
                <div class="header-logo">
                  <a class="site-title" rel="author" href="https://beta.pediatricurologybook.com/es/">
                    <img width="254" height="165" data-sticky-width="126" data-sticky-height="80" data-sticky-top="95" alt="Pedatric Urology Book" src="https://beta.pediatricurologybook.com/assets/site-img/pediatricurologybook-new.svg">
                  </a>
                </div>
              </div>
            </div>
            <div class="header-column justify-content-end">
              <div class="header-row pt-3 mb-3">
                <nav class="header-nav-top">
                  <ul class="nav nav-pills">
                    <li class="nav-item nav-item-anim-icon d-none d-md-block">
                      <a class="nav-link pl-0" href="https://beta.pediatricurologybook.com/es/about-us/"><i class="fa fa-angle-right pr-1"></i>Sobre Nosotros</a>
                    </li>
                    <li class="nav-item nav-item-anim-icon d-none d-md-block">
                      <a class="nav-link" href="https://beta.pediatricurologybook.com/es/contact-us/"><i class="fa fa-angle-right pr-1"></i>Contacta con Nosotros</a>
                    </li>
                    <li class="nav-item dropdown nav-item-left-border d-block nav-item-left-border-remove nav-item-left-border-md-show">
                      
                      <a class="nav-link" href="#" role="button" id="dropdown-language" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        <i class="fas fa-globe-americas"></i> Español
                        <i class="fas fa-angle-down"></i>
                      </a>
                      <div class="dropdown-menu" aria-labelledby="dropdown-language">
                        
                          
                          
                          
                          
                          <a class="dropdown-item" href="https://beta.pediatricurologybook.com/book/chapters/08-43_bladder-malignancies/">English</a>
                          
                        
                          
                            
                          
                          
                          
                          
                          <a class="dropdown-item" href="https://beta.pediatricurologybook.com/zh/book/chapters/08-43_bladder-malignancies/">简体中文</a>
                          
                        
                          
                          
                          
                          
                          <a class="dropdown-item" href="https://beta.pediatricurologybook.com/pt/book/chapters/08-43_bladder-malignancies/">Português</a>
                          
                        
                      </div>
                    </li>
                  </ul>
                </nav>
                <div class="header-nav-features header-nav-features-no-border header-nav-features-md-show-border d-none d-md-inline-flex">
                    <div class="simple-search input-group w-auto">
                      <input class="form-control text-1" id="search-input" name="q" type="text" value="" placeholder="Buscar...">
                      <span class="input-group-btn">
                        <button class="btn" type="submit">
                          <i class="fa fa-search"></i>
                        </button>
                      </span>
                      <ul id="search-results">
                      </ul>
                    </div>
                </div>
              </div>
              <div class="header-row">
                <div class="header-nav pt-1">
                  <div class="header-nav-main header-nav-main-effect-1 header-nav-main-sub-effect-1">
                    <nav class="collapse">
                      <ul class="nav nav-pills" id="mainNav">
                        <li><a href="https://beta.pediatricurologybook.com/es/"><i class="fas fa-home pr-1"></i>Inicio</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/book/"><i class="fas fa-book pr-1"></i>Leer el Libro</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/editors/"><i class="fas fa-pen-fancy pr-1"></i>Editores</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/contributors/"><i class="fas fa-code-branch pr-1"></i>Autores</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/sponsors/"><i class="fas fa-user-md pr-1"></i>Patrocinadores</a></li>
                      </ul>
                    </nav>
                  </div> <!-- end header-nav-main -->
                  <button class="btn header-btn-collapse-nav" data-toggle="collapse" data-target=".header-nav-main nav">
                      <i class="fas fa-bars"></i>
                  </button>
                </div> <!-- end header-nav -->
              </div> <!-- end header-row -->
            </div> <!-- end header-column -->
          </div> <!-- end header-row -->
        </div> <!-- end header-container -->
      </div> <!-- end header-body -->
    </header>
        
    
    <div role="main" class="main">
      <section class="page-header page-header-modern bg-color-primary page-header-md">
        <div class="container">
          <div class="row">
            <div class="col-md-8 order-2 order-md-1 align-self-center p-static">
              <h1>43: Bladder Malignancies</h1>
            </div>
            
            <div class="col-md-4 order-1 order-md-2 align-self-center">
              <ul class="breadcrumb d-block text-md-right breadcrumb-light">
              
                <li><a href="https://beta.pediatricurologybook.com/es/">Home</a></li>
              
                <li><a href="https://beta.pediatricurologybook.com/es/book/">Book</a></li>
              
                <li class="active"><a href="https://beta.pediatricurologybook.com/es/book/#section-08"> 08</a></li>
              </ul>
            </div>
          </div>
        </div>
      </section>
      <div class="container chapter chapter-08-43">
        <div class="row">
          <div class="col-lg-3 order-2 order-lg-1 mt-4 mt-lg-0 chapter-toc">
            <aside class="sidebar">
              <h5 class="font-weight-bold no_toc">Contenido del Capítulo</h5>
    
            <ul class="nav nav-list flex-column mb-5">
<li class="nav-item toc-h2"><a href="#introduction">Introduction</a></li>
<li class="nav-item toc-h2"><a href="#etiologypathogenesis">Etiology/Pathogenesis</a></li>
<li class="nav-item toc-h2"><a href="#evaluation-and-diagnosis">Evaluation and Diagnosis</a>
<ul>
<li class="nav-item toc-h3"><a href="#patient-presentation">Patient Presentation</a></li>
<li class="nav-item toc-h3"><a href="#initial-evaluation">Initial Evaluation</a></li>
<li class="nav-item toc-h3"><a href="#imaging-cystoscopy-and-cytology">Imaging, Cystoscopy and Cytology</a></li>
</ul>
</li>
<li class="nav-item toc-h2"><a href="#management">Management</a>
<ul>
<li class="nav-item toc-h3"><a href="#transurethral-resection-of-bladder-tumor-turbt">Transurethral resection of bladder tumor (TURBT)</a></li>
<li class="nav-item toc-h3"><a href="#intravesical-therapy">Intravesical therapy</a></li>
</ul>
</li>
<li class="nav-item toc-h2"><a href="#follow-up-and-surveillance">Follow up and Surveillance</a></li>
<li class="nav-item toc-h2"><a href="#bladder-tumors-in-the-neurogenic-bladder-population">Bladder Tumors in the Neurogenic Bladder Population</a></li>
<li class="nav-item toc-h2"><a href="#key-points">Key Points</a></li>
<li class="nav-item toc-h2"><a href="#conclusion">Conclusion</a></li>
<li class="nav-item toc-h2"><a href="#recommended-videos">Recommended videos</a></li>
<li class="nav-item toc-h2"><a href="#references">References</a></li>
</ul>
            
            </aside>
          </div>
          <div class="col-lg-9 order-1 order-lg-2 chapter-body">
            <p class="time-to-read"><i class="fas fa-info pr-2"></i><em>Le tomará aproximadamente 12 minutos leer este capítulo.</em></p>
                
            <p class="attribution">By <strong class="author-names">Jacqueline Morin, MD</strong> &amp; <strong class="author-names">Amanda F. Saltzman, MD</strong><br>
<em class="author-title">Department of Urology, University of Kentucky, Lexington, KY</em></p>

<h2 id="introduction">
<a class="anchor" href="#introduction" aria-hidden="true"><span class="octicon octicon-link"></span></a>Introduction</h2>

<p class="drop-caps">Urothelial cell carcinoma (<abbr title="urothelial cell carcinoma">UCC</abbr>) in the pediatric population is very rare with an incidence of roughly 0.1%-0.4%. A 2019 review found only 243 documented cases of <abbr title="urothelial cell carcinoma">UCC</abbr> in patients &lt;18y of age, with the mean age being 12.5y, and there is a male predominance (3:1). Overall, recurrence of <abbr title="urothelial cell carcinoma">UCC</abbr> in the pediatric population is thought to be low (8.6%), and death very uncommon, &lt;4%. Given its rarity, there are no published guidelines on the diagnosis and management of <abbr title="urothelial cell carcinoma">UCC</abbr> in the pediatric population. This chapter aims to outline etiology and pathogenesis, evaluation and diagnosis, management, and follow up of pediatric <abbr title="urothelial cell carcinoma">UCC</abbr> currently published literature.</p>

<h2 id="etiologypathogenesis">
<a class="anchor" href="#etiologypathogenesis" aria-hidden="true"><span class="octicon octicon-link"></span></a>Etiology/Pathogenesis</h2>

<p>There are well-defined risk factors for <abbr title="urothelial cell carcinoma">UCC</abbr> development in adults including smoking, exposures to various workplace chemicals such as aniline dyes and textile plant chemicals, phenacetin, and exposures to chemotherapy or radiation. Genetic conditions have also been linked to the development of bladder <abbr title="urothelial cell carcinoma">UCC</abbr> in adults, namely Lynch syndrome, Cowden disease, and presence of <abbr title="urothelial cell carcinoma">UCC</abbr> in first-degree relative. In children, genetic and environmental risk factors are not well studied, but extrapolated from adults. Early tobacco exposure, cancer-predisposition syndromes (e.g. Costello syndrome), abnormal bladder development, radiation exposure, cyclophosphamide exposure, and parasitic infections have been attributable risk factors for the development of <abbr title="urothelial cell carcinoma">UCC</abbr> in children. Despite these however, no obvious known risk factors may be present in nearly 87% of pediatric patients with <abbr title="urothelial cell carcinoma">UCC</abbr>.</p>

<p>Risk factors for recurrence and bladder cancer-related death in the pediatric population include family history of <abbr title="urothelial cell carcinoma">UCC</abbr>, high-grade histology, and larger tumors at diagnosis. Recurrence and death are rare, so again, these factors are generally extrapolated from the adult literature.</p>

<h2 id="evaluation-and-diagnosis">
<a class="anchor" href="#evaluation-and-diagnosis" aria-hidden="true"><span class="octicon octicon-link"></span></a>Evaluation and Diagnosis</h2>

<h3 id="patient-presentation">
<a class="anchor" href="#patient-presentation" aria-hidden="true"><span class="octicon octicon-link"></span></a>Patient Presentation</h3>

<p>Similar to adults, pediatric patients often present with painless gross hematuria (90%) although irritative voiding symptoms such as dysuria, frequency, and urgency may also be common. Delay in diagnosis by at least 1 year has been reported in up to 26% of patients given the rarity of this diagnosis in children and the generally benign differential diagnoses for gross hematuria in a child (e.g. benign urethrorrhagia, trauma, urinary tract infections, congenital urologic anomalies, intrinsic renal disease, voiding dysfunction, etc.).</p>

<p><abbr title="urothelial cell carcinoma">UCC</abbr> typically presents as a solitary bladder tumor in children compared to multifocality in adults (94% vs. 6%). 93.4% of tumors are low-grade (pTa or pT1), and there is usually no evidence of nodal involvement or metastasis. (<a href="#table-1" class="table-link">Table 1</a>) outlines the American Join Committee on Cancer (<abbr title="American Joint Committee on Cancer">AJCC</abbr>) bladder cancer staging.</p>

<p><strong id="table-1" class="table-number">Table 1</strong> <abbr title="American Joint Committee on Cancer">AJCC</abbr> Urothelial cell carcinoma staging</p>

<table>
  <thead>
    <tr>
      <th>T stage</th>
      <th>Description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Ta</td>
      <td>Noninvasive papillary carcinoma</td>
    </tr>
    <tr>
      <td>Tis</td>
      <td>Carcinoma in situ (<abbr title="carcinoma in situ">CIS</abbr>)</td>
    </tr>
    <tr>
      <td>T1</td>
      <td>Tumor invades lamina propria</td>
    </tr>
    <tr>
      <td>T2</td>
      <td>Tumor invades muscularis propria</td>
    </tr>
    <tr>
      <td>T2a</td>
      <td>Tumor invades superficial muscularis propria (inner half)</td>
    </tr>
    <tr>
      <td>T2b</td>
      <td>Tumor invades deep muscularis propria (outer half)</td>
    </tr>
    <tr>
      <td>T3</td>
      <td>Tumor invades perivesical tissue/fat</td>
    </tr>
    <tr>
      <td>T3a</td>
      <td>Tumor invades perivesical tissue/fat microscopically</td>
    </tr>
    <tr>
      <td>T3b</td>
      <td>Tumor invades perivesical tissue fat macroscopically (extravesical mass)</td>
    </tr>
    <tr>
      <td>T4</td>
      <td>Tumor invades prostate, uterus, vagina, pelvic wall, or abdominal wall</td>
    </tr>
    <tr>
      <td>T4a</td>
      <td>Tumor invades adjacent organs (uterus, ovaries, prostate stroma)</td>
    </tr>
    <tr>
      <td>T4b</td>
      <td>Tumor invades pelvic wall and/or abdominal wall</td>
    </tr>
  </tbody>
</table>

<h3 id="initial-evaluation">
<a class="anchor" href="#initial-evaluation" aria-hidden="true"><span class="octicon octicon-link"></span></a>Initial Evaluation</h3>

<p>The 2020 <abbr title="American Urological Association">AUA</abbr> guidelines on non-muscle invasive <abbr title="urothelial cell carcinoma">UCC</abbr> stipulate clear recommendations on evaluation of adult patients with gross hematuria including cystoscopy, upper tract imaging with <abbr title="computed tomography">CT</abbr> or <abbr title="magnetic resonance">MR</abbr> urography, and occasionally the use of urine cytology. Given the natural progression of <abbr title="urothelial cell carcinoma">UCC</abbr> in pediatric patients, i.e. generally low grade tumors that do not recur, the initial workup of a pediatric patient with gross hematuria is often approached less aggressively.</p>

<p>Evaluation should begin with a history and physical exam. Additional investigative modalities at the first visit include urinalysis (with particular attention given to presence/quantity of red blood cells and indicators of infection such as leukocyte esterase, nitrites, and bacteria), urine culture, and bladder/renal ultrasound.</p>

<p>Urinalysis can confirm ongoing microscopic hematuria and help to rule out other potential causes of hematuria, including medical renal disease or infection. The urine culture would confirm no infection is present. Bladder/renal ultrasound can determine upper and lower tract anatomy and evaluate potential causes of gross hematuria. Given the smaller body habitus of children, this modality can be very sensitive in detecting small luminal tumors.</p>

<h3 id="imaging-cystoscopy-and-cytology">
<a class="anchor" href="#imaging-cystoscopy-and-cytology" aria-hidden="true"><span class="octicon octicon-link"></span></a>Imaging, Cystoscopy and Cytology</h3>

<p>In the adult population, cystoscopy is the gold standard for the detection of bladder tumors and upper tract imaging in the form of <abbr title="computed tomography">CT</abbr> or <abbr title="magnetic resonance">MR</abbr> urography is standard to image the upper tracts. In the pediatric population there are considerations that must be weighed, including the requirement for general anesthesia for cystoscopy, sedation for imaging with <abbr title="computed tomography">CT</abbr> or <abbr title="magentic resonance imaging">MRI</abbr>, and radiation exposure with <abbr title="computed tomography">CT</abbr>.</p>

<p>There have been a few studies evaluating the sensitivity and specificity of ultrasound in evaluation of both upper and lower urinary tracts for detection of masses in children. Bladder ultrasound has been found to have sensitivity of 83-93% in detecting bladder tumors with 93-100% specificity and has detected bladder lesions as small as 5mm. When considering the cumulative radiation dose a pediatric patient may acquire for <abbr title="urothelial cell carcinoma">UCC</abbr> surveillance over many years, ultrasound becomes an attractive modality both for an initial screening test upon presentation with gross hematuria but also for surveillance of mass recurrence following resection.</p>

<p>Cystoscopy is indicated for patients for whom a bladder lesion was detected on ultrasound or for those with persistent hematuria without any other explanation. In pediatric patients, tumors are usually solitary, non-invasive, and approximately 52% of them are found on the lateral walls (<a href="#figure-1" class="figure-link">Figure 1</a>) Cystoscopy in children requires anesthesia, thus cystoscopy is often performed with transurethral resection of bladder tumor (<abbr title="transurethral resection bladder tumor">TURBT</abbr>) as an expected part of the procedure. Tissue is required to establish a diagnosis and depth of invasion (T stage). This is also the initial treatment to remove the entire tumor.</p>

<p><img src="https://beta.pediatricurologybook.com/assets/figures/figure-43-1.png" alt="Figure 1" class="float-start img-fluid"> 
<strong id="figure-1" class="figure-number">Figure 1</strong> Examples of bladder tumors. Bladder tumors are often solitary and papillary (a, b) and can be harder to identify in patients who have undergone bladder augmentation (c, d).</p>

<p>There is minimal role for urine cytology in pediatric patients as these bladder tumors are typically low-grade and the sensitivity of cytology for low-grade tumors is quite low.</p>

<h2 id="management">
<a class="anchor" href="#management" aria-hidden="true"><span class="octicon octicon-link"></span></a>Management</h2>

<p>Bladder cancer recurrence in the pediatric population is low and 5-year survival rates are favorable at 97.3%. Because of these differences, management differs significantly from adults. There are, however, some similarities between both populations and thus there are some shared aspects to management.</p>

<h3 id="transurethral-resection-of-bladder-tumor-turbt">
<a class="anchor" href="#transurethral-resection-of-bladder-tumor-turbt" aria-hidden="true"><span class="octicon octicon-link"></span></a>Transurethral resection of bladder tumor (<abbr title="transurethral resection bladder tumor">TURBT</abbr>)</h3>

<p>As with adults, transurethral resection is both diagnostic and therapeutic. This requires resection of all grossly evident tumor, with depth sufficient to obtain sampling of the underlying detrusor muscle. This is necessary to reduce the risk of recurrence but also for adequate staging. TURBTs that require a resectoscope may be prohibitive in small patients as resectoscope loops can be very challenging to work with on smaller scopes. Some children may require cold cup biopsy and fulguration of the tumor base, although care must be taken to obtain deep tissue biopsies for detrusor sampling. Bimanual exam of the bladder should also be performed at time of <abbr title="transurethral resection bladder tumor">TURBT</abbr> to complete staging.</p>

<h3 id="intravesical-therapy">
<a class="anchor" href="#intravesical-therapy" aria-hidden="true"><span class="octicon octicon-link"></span></a>Intravesical therapy</h3>

<p>In general, perioperative chemotherapy instillation is not used for pediatric patients. Pediatric patients who are found to have higher grade and stage tumors are likely to behave more similarly to adult <abbr title="urothelial cell carcinoma">UCC</abbr> and thus may be best treated as such, although prospective studies of this rare scenario do not exist. These patients may require intravesical chemotherapy and surveillance protocols as those for adults outlined by the <abbr title="American Urological Association">AUA</abbr> and <abbr title="National Comprehensive Cancer Network">NCCN</abbr> organizations. There are some reports of post-<abbr title="transurethral resection bladder tumor">TURBT</abbr> use of intravesical instillation <abbr title="Bacillus Calmette–Guérin">BCG</abbr>, mitomycin, or epirubicin in pediatric patients with bladder cancer. Generally, doses and regimens have been that which is described in adults, with few severe adverse events. Intravesical therapy is typically reserved for patients with high-grade or recurrent disease, but data are limited to case reports, so there are no clear data to establish a well-defined role at this time.</p>

<h2 id="follow-up-and-surveillance">
<a class="anchor" href="#follow-up-and-surveillance" aria-hidden="true"><span class="octicon octicon-link"></span></a>Follow up and Surveillance</h2>

<p>Adult guidelines have aggressive, clear, and established regimens for surveillance and management of recurrences as this is commonplace. For children however, there are no clear recommendations due to the rarity of this tumor and the even more rare recurrence. A 2019 review reported just an 8.6% recurrence rate, a significant difference from adults.</p>

<p>Generally, the type and timing of surveillance should be tailored based on the child’s risk of relapse. The number of lesions, pathologic stage and grade, tumor size, history of recurrence, and age should all be considered. Regular screening with ultrasound is a reasonable option for children with diagnosed bladder cancer due to its high sensitivity and non-invasive nature. Cystoscopy can subsequently be performed if a lesion is detected. Routine surveillance cystoscopy despite normal ultrasounds may be required in higher risk pediatric patients (e.g. multiple lesions, high-grade lesions, recurrence, older age, etc.). Similar to at the time of diagnosis, urine cytology is unlikely to yield much benefit given that children typically have low-grade well-differentiated tumors.</p>

<p>Unlike adult protocols, there are no data to guide the length of surveillance for children with <abbr title="urothelial cell carcinoma">UCC</abbr>. One large literature review found that if a recurrence or death related to low-grade/stage <abbr title="urothelial cell carcinoma">UCC</abbr> were to occur, it is likely to occur in the first year of initial diagnosis. The average time to recurrence or death was found to be 8.6 months.</p>

<p><strong id="table-2" class="table-number">Table 2</strong> Surveillance schedule for low-grade, low-stage bladder <abbr title="urothelial cell carcinoma">UCC</abbr> in pediatric patients (adapted by Rezaee <em>et al</em>)<a class="citation" href="#rezaee2019a"><span style="vertical-align: super">1</span></a></p>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>0-12 months</th>
      <th>18-24 months</th>
      <th>36-48 months</th>
      <th>&gt;60 months</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Ultrasound</td>
      <td>Every 3 mos</td>
      <td>Every 6 mos</td>
      <td>Annually</td>
      <td>At discretion of provider</td>
    </tr>
    <tr>
      <td>Urinalysis</td>
      <td>Every 3 mos</td>
      <td>Every 6 mos</td>
      <td>Annually</td>
      <td>At discretion of provider</td>
    </tr>
    <tr>
      <td>Cystoscopy</td>
      <td>Every 3 mos</td>
      <td>Every 6 mos</td>
      <td>+/- Annually</td>
      <td>At discretion of provider</td>
    </tr>
    <tr>
      <td>Cytology</td>
      <td>—</td>
      <td>—</td>
      <td>—</td>
      <td>—</td>
    </tr>
  </tbody>
</table>

<p>Additionally, it is very unlikely that a recurrence or death event would occur beyond three years after initial diagnosis and treatment. The most remote recurrence published is at 32 months after initial diagnosis. A potential surveillance schedule for low grade, low stage <abbr title="urothelial cell carcinoma">UCC</abbr> was outlined by Rezaee <em>et al.</em> based on a 2019 literature review cohort, and this is summarized in (<a href="#table-2" class="table-link">Table 2</a>) It is important to note that this surveillance schedule has not been rigorously studied by a prospective randomized study proving its safety and is outlined as a starting point for low grade/stage disease only.</p>

<h2 id="bladder-tumors-in-the-neurogenic-bladder-population">
<a class="anchor" href="#bladder-tumors-in-the-neurogenic-bladder-population" aria-hidden="true"><span class="octicon octicon-link"></span></a>Bladder Tumors in the Neurogenic Bladder Population</h2>

<p>Long-term follow up of patients with a congenital neurogenic bladder (i.e. spina bifida, bladder exstrophy, etc.) have identified this population to be uniquely at higher risk for the development of bladder cancer (estimated incidence about 4%). Unlike bladder cancer in the non-neurogenic bladder population, this cohort is usually diagnosed incidentally and has a higher incidence of adenocarcinoma (50%). The vast majority of patients present with locally advanced or widespread disease (&gt;70%) and survival is poor. Diagnosis is often made with late stage disease and outcomes are poor.</p>

<p>Initial postulation for this increased risk of bladder cancer centered around augmentation cystoplasty being a risk factor. While gastric segments certainly increase the subsequent risk of malignancy, augmentation with other bowel segments do not appear to increase the risk of malignancy. Through various retrospective studies, it now appears that the risk of malignancy is due to the congenital bladder itself rather than due to augmentation.</p>

<p>When early descriptions of advanced, deadly malignancies in this population were first published, a variety of measures were suggested and then studied with an aim of earlier detection of these tumors. Unfortunately, none have proven beneficial. Annual cystoscopy is of low yield and even in patients with normal screening, advanced bladder cancer did develop. It was suggested that if cystoscopy could detect every malignancy, 980 would need to be performed to diagnose a single case of cancer over 10y of follow up. Urine cytology is of little value in this population due to chronic pyuria, intermittent catheterizations, and expected enteric cell shedding and it also has a high false positive rate. When then including effectiveness of the above screening measures, is appears that the increase in life expectancy was only 2.3 months and lifetime cost was &gt;$55,000 per capita. This is mainly driven by the low rates of malignancy and the large number of screening tests needed to detect a single case of malignancy, independent of stage at diagnosis.</p>

<p>The Husmann protocol has been widely adopted to guide follow up for patients with neurogenic bladder, both for malignancy detection as well as routine assessment for patients with or without bladder reconstruction (<a href="#figure-2" class="figure-link">Figure 2</a>) This involves an annual assessment of urinary tract infections, hematuria, bladder/pelvic/flank pain and new incontinence. If there are any abnormalities or changes from baseline, urine culture, cystoscopy, <abbr title="computed tomography">CT</abbr> scan ± urodynamics should be considered. All patients should have annual creatinine/cystatin C, electrolytes, serum B12 level and urinalysis. Similarly, if there are &lt;50 <abbr title="red blood cells">RBCs</abbr>/hpf, renal/bladder <abbr title="ultrasound">US</abbr> should be ordered. If the <abbr title="ultrasound">US</abbr> is abnormal, if there is gross hematuria or ≥50 <abbr title="red blood cells">RBCs</abbr>/hpf, then urine culture, cystoscopy, <abbr title="computed tomography">CT</abbr> scan ± urodynamics should be considered.  For patients with colonic segments, routine cystoscopy for colon cancer screening should begin at age 50y.</p>

<p><img src="https://beta.pediatricurologybook.com/assets/figures/figure-43-2.svg" alt="Figure 2" class="float-start img-fluid"><br>
<strong id="figure-2" class="figure-number">Figure 2</strong> Husmann protocol for surveillance of bladder cancer in patients with bladder augmentations.<a class="citation" href="#husmann2011a"><span style="vertical-align: super">2</span></a></p>

<h2 class="key-points-head" id="key-points">
<a class="anchor" href="#key-points" aria-hidden="true"><span class="octicon octicon-link"></span></a>Key Points</h2>

<ul class="key-points-list">
  <li>Bladder cancer in pediatric patients is rare</li>
  <li>There are currently no well-defined risk factors for the development of pediatric bladder cancer, but the risk factors from adults are extrapolated and often applied to this population</li>
  <li>Most pediatric patients with bladder cancer present with painless gross hematuria or irritative voiding symptoms</li>
  <li>Most pediatric <abbr title="urothelial cell carcinoma">UCC</abbr> is low-grade, low-stage, and does not recur</li>
  <li>Initial evaluation should start with history and physical, urinalysis, urine culture, and bladder/renal ultrasound</li>
  <li>Bladder ultrasound has excellent sensitivity and specificity for detection of bladder tumors and should be considered as a screening modality</li>
  <li>There is no role for urine cytology as most pediatric <abbr title="urothelial cell carcinoma">UCC</abbr> is low-grade</li>
  <li>If a lesion is found on ultrasound, cystoscopy with <abbr title="transurethral resection bladder tumor">TURBT</abbr> should be performed</li>
  <li>Transurethral resection of bladder tumor should include detrusor sampling for proper staging</li>
  <li>The role for intravesical chemotherapy is unclear, but is a reasonable consideration for patients with high-stage, high-grade, or recurrent disease</li>
  <li>Pediatric patients with <abbr title="urothelial cell carcinoma">UCC</abbr> should undergo surveillance at least for the first 3y after diagnosis, but surveillance beyond this may be unnecessary</li>
  <li>Patients with a congenital neurogenic bladder (<abbr title="congenital neurogenic bladder">CNB</abbr>) are at higher risk of bladder cancer and this risk is not associated with bladder augmentation other than gastric segments; pathology is usually adenocarcinoma</li>
  <li>
<abbr title="congenital neurogenic bladder">CNB</abbr> patients present incidentally with higher stage and locally advanced tumors, with poor survival</li>
  <li>Routine screening with cystoscopy and urine cytology is not beneficial and is not recommended</li>
  <li>The Husmann protocol is advocated for follow up for patients with <abbr title="congenital neurogenic bladder">CNB</abbr> with a goal of targeted identification of patients at higher risk for malignancy (hematuria, increased <abbr title="urinary tract infection">UTIs</abbr>, pain, new incontinence, abnormal labs/imaging)</li>
</ul>

<h2 id="conclusion">
<a class="anchor" href="#conclusion" aria-hidden="true"><span class="octicon octicon-link"></span></a>Conclusion</h2>

<p>Bladder cancer in pediatric patients is rare and overall carries a good prognosis. Most tumors are solitary, low-grade, and do not recur. Workup should start with history and physical, urinalysis, urine culture, and bladder/renal ultrasound, with subsequent cystoscopy and <abbr title="transurethral resection bladder tumor">TURBT</abbr> of the bladder lesion. Intravesical chemotherapy can often be avoided given low-grade pathology. In high-grade or higher-stage tumors or with recurrent tumors, intravesical chemotherapy can be considered, however, there are no evidence-based guidelines on its use in children presently. Patients should be monitored for a duration of at least 3y with a combination of periodic urinalyses, bladder/renal ultrasounds, and cystoscopy. Surveillance beyond 3y may not be necessary, but shared-decision making should be utilized to determine this duration.</p>

<h2 class="rec-videos-head" id="recommended-videos">
<a class="anchor" href="#recommended-videos" aria-hidden="true"><span class="octicon octicon-link"></span></a>Recommended videos</h2>

<ul class="rec-videos-list">
  <li><a href="https://university.auanet.org/core/oncology-adult/bladder-neoplasms-non-muscle-invasive-bladder-cancer/"><abbr title="American Urological Association">AUA</abbr> University, oncology, adult, non-muscle invasive bladder cancer, videos 1 and 2</a></li>
</ul>

<h2 id="references">
<a class="anchor" href="#references" aria-hidden="true"><span class="octicon octicon-link"></span></a>References</h2>

<ol class="bibliography">
<li>
<span id="karatzas2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Karatzas A, Tzortzis V</b></span>. <span style="font-variant: normal">Lower urinary tract symptoms and bladder cancer in
    children: The hidden scenario</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Urol Ann</i></span> <span style="text-decoration: none">2019; <b>11</b> (1)</span>: <span style="text-decoration: none">102–104</span>. <span style="text-decoration: underline">DOI: 10.4103/UA.UA_60_18</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/30787582" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.4103/UA.UA_60_18" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="rezaee2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Rezaee ME, Dunaway CM, Baker ML, Penna FJ, Chavez DR</b></span>. <span style="font-variant: normal">Urothelial cell carcinoma of the bladder in
    pediatric patients: a systematic review and data analysis of the
    world literature</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Journal of Pediatric Urology</i></span> <span style="text-decoration: none">2019; <b>15</b> (4)</span>: <span style="text-decoration: none">309–314</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpurol.2019.06.013</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/31326327" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpurol.2019.06.013" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="lerena2010a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Lerena J, Krauel L, García-Aparicio L, Vallasciani S, Suñol M, Rodó J</b></span>. <span style="font-variant: normal">Transitional cell carcinoma of the bladder in
    children and adolescents: Six-case series and review of the
    literature</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Journal of Pediatric Urology</i></span> <span style="text-decoration: none">2010; <b>6</b> (5)</span>: <span style="text-decoration: none">481–485</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpurol.2009.11.006</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/20080447" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpurol.2009.11.006" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="egbers2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Egbers L, Grotenhuis AJ, Aben KK, Alfred Witjes J, Kiemeney LA, Vermeulen SH</b></span>. <span style="font-variant: normal">The prognostic value of family history among
    patients with urinary bladder cancer</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Int J Cancer</i></span> <span style="text-decoration: none">2015; <b>136</b> (5)</span>: <span style="text-decoration: none">1117–1124</span>. <span style="text-decoration: underline">DOI: 10.1002/ijc.29062</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/24978702" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1002/ijc.29062" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="wild2007a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Wild P, Giedl J, Stoehr R</b></span>. <span style="font-variant: normal">Genomic aberrations are rare in urothelial neoplasms
    of patients 19 years or younger</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>The Journal of Pathology</i></span> <span style="text-decoration: none">2007; <b>211</b> (1)</span>: <span style="text-decoration: none">18–25</span>. <span style="text-decoration: underline">DOI: 10.1002/path.2075</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/17072825" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1002/path.2075" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="fine2005a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI</b></span>. <span style="font-variant: normal">Urothelial Neoplasms In Patients 20 Years or
    Younger: A Clinicopathological Analysis Using The World Health
    Organization 2004 Bladder Consensus Classification</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Journal of Urology</i></span> <span style="text-decoration: none">2005; <b>174</b> (5)</span>: <span style="text-decoration: none">1976–1980</span>. <span style="text-decoration: underline">DOI: 10.1097/01.ju.0000176801.16827.82</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/16217372" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1097/01.ju.0000176801.16827.82" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="paner-a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Paner GP, Zehnder P, Amin AM, Husain AN, Desai MM</b></span>. <span style="font-variant: normal">Urothelial Neoplasms of the Urinary Bladder
    Occurring in Young Adult and Pediatric Patients: A Comprehensive
    Review of Literature With Implications for Patient Management</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Adv Ant Pathol</i></span> <span style="text-decoration: none"><b>18</b> (1)</span>: <span style="text-decoration: none">79–89</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/21169741" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a>
</li>
<li>
<span id="unknown-a"><span style="font-weight: normal; text-decoration: none"><span style="font-variant: normal">Bladder Cancer: Non-Muscle Invasive Guideline -
    American Urological Association</span>. .</span></span> <a href="https://www.auanet.org/guidelines/guidelines/bladder-cancer-non-muscle-invasive-guideline" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a>
</li>
<li>
<span id="gharibvand2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Gharibvand MM, Kazemi M, Motamedfar A, Sametzadeh M, Sahraeizadeh A</b></span>. <span style="font-variant: normal">The role of ultrasound in diagnosis and evaluation
    of bladder tumors</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Family Med Prim Care</i></span> <span style="text-decoration: none">2017; <b>6</b> (4)</span>: <span style="text-decoration: none">840–843</span>. <span style="text-decoration: underline">DOI: 10.4103/jfmpc.jfmpc_186_17</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29564274" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.4103/jfmpc.jfmpc_186_17" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="berretini2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Berretini A, Castagnetti M, Salerno A</b></span>. <span style="font-variant: normal">Bladder urothelial neoplasms in pediatric age:
    Experience at three tertiary centers</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Journal of Pediatric Urology</i></span> <span style="text-decoration: none">2015; <b>11</b></span>: <span style="text-decoration: none">26 1–26 5</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpurol.2014.08.008</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/25305695" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpurol.2014.08.008" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="d2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>D DC, A F, K P</b></span>. <span style="font-variant: normal">Management and follow-up of urothelial neoplasms of
    the bladder in children: A report from the TREP project</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Pediatric Blood &amp; Cancer</i></span> <span style="text-decoration: none">2015; <b>62</b> (6)</span>: <span style="text-decoration: none">1000–1003</span>. <span style="text-decoration: underline">DOI: 10.1002/pbc.25380</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/25545665" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1002/pbc.25380" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="elsharnoby2021a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>ElSharnoby O, Fraser N, Williams A, Scriven S, Shenoy M</b></span>. <span style="font-variant: normal">Bladder urothelial cell carcinoma as a rare cause of
    haematuria in children: Our experience and review of current
    literature</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Journal of Pediatric Surgery Published Online
    September</i></span> <span style="text-decoration: none">2021; <b>17</b></span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpedsurg.2021.09.007</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/34563358" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpedsurg.2021.09.007" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="saltsman2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltsman JA, Malek MM, Reuter VE</b></span>. <span style="font-variant: normal">Urothelial neoplasms in pediatric and young adult
    patients: A large single-center series</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Journal of Pediatric Surgery</i></span> <span style="text-decoration: none">2018; <b>53</b> (2)</span>: <span style="text-decoration: none">306–309</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpedsurg.2017.11.024</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29221636" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpedsurg.2017.11.024" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="rague2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Rague JT, High-grade LRSM</b></span>. <span style="font-variant: normal">Nonmuscle Invasive Urothelial Carcinoma in a
    Prepubertal Patient With TURBT and Intravesical BCG</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Urology</i></span> <span style="text-decoration: none">2019; <b>124</b></span>: <span style="text-decoration: none">257–259</span>. <span style="text-decoration: underline">DOI: 10.1016/j.urology.2018.10.028</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/30366046" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.urology.2018.10.028" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="peard2020a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Peard L, Stark T, Ziada A, Saltzman AF</b></span>. <span style="font-variant: normal">Recurrent Bladder Cancer in a Teenage Male</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Urology</i></span> <span style="text-decoration: none">2020; <b>141</b></span>: <span style="text-decoration: none">135–138</span>. <span style="text-decoration: underline">DOI: 10.1016/j.urology.2020.04.031</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/32333990" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.urology.2020.04.031" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="soergel2004a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Soergel TM, Cain MP, Misseri R, Gardner TA, Koch MO, Rink RC</b></span>. <span style="font-variant: normal">TRANSITIONAL CELL CARCINOMA OF THE BLADDER FOLLOWING
    AUGMENTATION CYSTOPLASTY FOR THE NEUROPATHIC BLADDER</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>The Journal of Urology</i></span> <span style="text-decoration: none">2004; <b>172</b> (4, Supplement)</span>: <span style="text-decoration: none">1649–1652</span>. <span style="text-decoration: underline">DOI: 10.1097/01.ju.0000140194.87974.56</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/15371782" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1097/01.ju.0000140194.87974.56" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="austin2007a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Austin JC, Elliott S, Cooper CS</b></span>. <span style="font-variant: normal">Patients With Spina Bifida and Bladder Cancer:
    Atypical Presentation, Advanced Stage and Poor Survival</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>The Journal of Urology</i></span> <span style="text-decoration: none">2007; <b>178</b> (3)</span>: <span style="text-decoration: none">798–801</span>. <span style="text-decoration: underline">DOI: 10.1016/j.juro.2007.05.055</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/17631349" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.juro.2007.05.055" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="rove2016a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Rove K, Higuchi T</b></span>. <span style="font-variant: normal">Monitoring and malignancy concerns in patients with
    congenital bladder anomalies</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Current Opinion in Urology</i></span> <span style="text-decoration: none">2016; <b>26</b> (4)</span>: <span style="text-decoration: none">344–350</span>. <span style="text-decoration: underline">DOI: 10.1097/MOU.0000000000000297</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/27139193" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1097/MOU.0000000000000297" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="husmann2011a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Husmann D, Fox J, Higuchi T</b></span>. <span style="font-variant: normal">Malignancy following bladder
    augmentation:recommendations for long-term follow-up and cancer
    screening</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>AUA Update Ser</i></span> <span style="text-decoration: none">2011; <b>30</b> (24)</span>: <span style="text-decoration: none">222–227</span></span>.</span></span> </li>
<li>
<span id="higuchi2011a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Higuchi TT, Fox JA, Husmann DA</b></span>. <span style="font-variant: normal">Annual Endoscopy and Urine Cytology for the
    Surveillance of Bladder Tumors After Enterocystoplasty for
    Congenital Bladder Anomalies</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>The Journal of Urology</i></span> <span style="text-decoration: none">2011; <b>186</b> (5)</span>: <span style="text-decoration: none">1791–1795</span>. <span style="text-decoration: underline">DOI: 10.1016/j.juro.2011.07.028</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/21944100" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.juro.2011.07.028" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="hamid2009a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Hamid R, Greenwell TJ, Nethercliffe JM, Freeman A, Venn SN, Woodhouse CRJ</b></span>. <span style="font-variant: normal">Routine surveillance cystoscopy for patients with
    augmentation and substitution cystoplasty for benign urological
    conditions: is it necessary?</span> <span style="text-decoration: underline"><span style="text-decoration: none"><i>BJU International</i></span> <span style="text-decoration: none">2009; <b>104</b> (3)</span>: <span style="text-decoration: none">392–395</span>. <span style="text-decoration: underline">DOI: 10.1111/j.1464-410X.2009.08401.x</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/19239457" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/j.1464-410X.2009.08401.x" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="kokorowski2011a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Kokorowski PJ, Routh JC, Borer JG, Estrada CR, Bauer SB, Nelson CP</b></span>. <span style="font-variant: normal">Screening for Malignancy After Augmentation
    Cystoplasty in Children With Spina Bifida: A Decision Analysis</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>The Journal of Urology</i></span> <span style="text-decoration: none">2011; <b>186</b> (4)</span>: <span style="text-decoration: none">1437–1443</span>. <span style="text-decoration: underline">DOI: 10.1016/j.juro.2011.05.065</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/21855939" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.juro.2011.05.065" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
</ol>


            
            <!--Last repository commit: 3033c65-->
            <p class="last-modified"><i class="fas fa-clock pr-2"></i><em>Última actualización: 2022-08-16 15:46</em></p>
          </div> <!-- /col -->
        </div> <!-- /row -->
      </div> <!-- /container -->
    </div> <!-- /main -->
    
    <footer id="footer">
      <div class="container">
        <div class="row py-5">
          <div class="col-md-4 d-flex justify-content-center justify-content-md-start mb-4 mb-lg-0">
            <a href="https://beta.pediatricurologybook.com/es/" class="logo pr-0 pr-lg-3 pl-3 pl-md-0">
                <img alt="Pediatric Urology Book" class="img-responsive" src="https://beta.pediatricurologybook.com/assets/site-img/pediatricurologybook-white.svg">
            </a>
          </div>
        </div>
      </div>
      <div class="footer-copyright footer-copyright-style-2">
        <div class="container py-2">
          <div class="row py-4">
            <div class="col-lg-4 d-flex align-items-end justify-content-center justify-content-md-start mb-2 mb-lg-0">
              <p>© 2023 por <a href="https://beta.pediatricurologybook.com/es/">Pediatric Urology Book</a>. Todos los derechos reservados.</p>
            </div>
            <div class="col-lg-8 d-flex flex-column mb-4 mb-lg-0">
              <div class="row">
                <div class="col-12 d-flex align-items-center justify-content-center justify-content-md-end m-0 p-0"><ul class="footer-social-icons social-icons social-icons-clean social-icons-icon-light"><li class="social-icons-github"><a href="https://www.github.com/kylerove/pediatricurologybook" target="_blank" title="GitHub"><i class="fab fa-github-alt"></i></a></li><li class="social-icons-twitter"><a href="https://www.twitter.com/PedUrologyBook" target="_blank" title="Twitter"><i class="fab fa-twitter"></i></a></li><li class="social-icons-mastodon"><a rel="me" href="https://med-mastodon.com/@pediatricurologybook" target="_blank" title="Mastodon"><i class="fab fa-mastodon"></i></a></li><li class="social-icons-youtube"><a href="https://www.youtube.com/@pediatricurologybook" target="_blank" title="Youtube"><i class="fab fa-youtube"></i></a></li></ul></div>
              </div>
              <div class="row">
                <div class="col-12 d-flex align-items-center justify-content-center justify-content-md-end m-0 p-0">
                  <nav id="sub-menu">
                    <ul>
                      <li><i class="fas fa-map-marker"></i> <a href="https://beta.pediatricurologybook.com/es/site-map/">Mapa del Sitio</a></li><li><i class="fas fa-envelope"></i><a href="mailto:editors%40pediatricurologybook.com" class="opacity-7 pl-1">editors@pediatricurologybook.com</a></li></ul>
                  </nav>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </footer>
</div>
    
    <!-- Search -->
    <script src="https://beta.pediatricurologybook.com/assets/js/search.min.js"></script>
    
    <!-- Vendor -->
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery/jquery.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.appear/jquery.appear.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.easing/jquery.easing.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.validation/jquery.validate.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.stupidtable/stupidtable.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/popper/umd/popper.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/bootstrap/js/bootstrap.min.js"></script>
    
    <!-- Theme Base, Components and Settings -->
    <script src="https://beta.pediatricurologybook.com/assets/js/theme.js"></script>
    
    <!-- Current Page --><script src="https://beta.pediatricurologybook.com/assets/js/pages/chapter.js"></script>
    
    
    <!-- Theme Custom -->
    <script src="https://beta.pediatricurologybook.com/assets/js/custom.js"></script>
    
    <!-- Theme Initialization Files -->
    <script src="https://beta.pediatricurologybook.com/assets/js/theme.init.js"></script>
    
    <!-- Scroll to top -->
    <a class="scroll-to-top hidden-mobile" href="#"><i class="fas fa-chevron-up"></i></a>
    
  </body>
</html>
